EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #100-0785_C
cGMP，人T细胞激活和扩增试剂
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
无需使用磁珠、饲养层细胞或抗原，即可实现强劲的人T细胞激活与扩增。
该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。
ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。
包含
• 抗人CD3单特异性抗体复合物
• 抗人CD28单特异性抗体复合物
• 抗人CD2单特异性抗体复合物
• 含0.02% TWEEN® 20的磷酸盐缓冲液 (PBS)
分类
添加剂
细胞类型
T 细胞，T 细胞，CD4+，T 细胞，CD8+
种属
人
应用
激活，细胞培养，扩增
品牌
ImmunoCult
研究领域
癌症，免疫，细胞治疗开发
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (7)
文献 (24)
CD137L promotes immune surveillance in melanoma via HLTF regulation
Nature Communications 2025 Sep
Abstract
Immune checkpoint blockers (ICBs) have demonstrated substantial efficacy across various malignancies, yet the benefits of ICBs are limited to a subset of patients. Therefore, it is essential to identify novel therapeutic targets. By integrating multi-omics data from cohorts of patients with melanoma treated with ICBs, a positive correlation is observed between tumor CD137L expression and the efficacy of PD-1 blockade. Functionally, CD137L induction in cancer cells significantly enhances anti-tumor immunity by promoting CD8 + T cell survival, both in vivo and in vitro. Mechanistically, helicase-like transcription factor (HLTF) is identified as a pivotal transcriptional regulator of CD137L , controlling its expression through phosphorylation of serine at position 398. Therapeutically, the AMPK agonist AICAR (acadesine) as an inducer of CD137L , exhibiting synergistic effects with PD-1 or CTLA-4 blockade. In summary, our findings elucidate a mechanism controlling CD137L expression and highlight a promising combination therapy to enhance the efficacy of ICBs in melanoma. One Sentence Summary: Inducing co-stimulatory immune checkpoint CD137L expression in melanoma cells enhances T cell-mediated anti-tumor immunity. Subject terms: Tumour immunology, Cancer immunotherapy
Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity
Journal of Hematology & Oncology 2025 Oct
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of ER, PR, and HER2 expression. Its aggressive behavior, high degree of tumor heterogeneity, and immunosuppressive tumor microenvironment (TME) are associated with poor clinical outcomes, rapid disease progression, and limited therapeutic options. Although chimeric antigen receptor (CAR)-engineered T cell therapy has shown certain promise, its applicability in TNBC is hindered by antigen escape, TME-mediated suppression, and the logistical constraints of autologous cell production. In this study, we employed hematopoietic stem and progenitor cell (HSPC) gene engineering and a feeder-free HSPC differentiation culture to generate allogeneic IL-15-enhanced, mesothelin-specific CAR-engineered invariant natural killer T ( Allo15 MCAR-NKT) cells. These cells demonstrated robust and multifaceted antitumor activity against TNBC, mediated by CAR- and NK receptor-dependent cytotoxicity, as well as selective targeting of CD1d + TME immunosuppressive cells through their TCR. In both orthotopic and metastatic TNBC xenograft models, Allo15 MCAR-NKT cells demonstrated potent antitumor activity, associated with robust effector and cytotoxic phenotypes, low exhaustion, and a favorable safety profile without inducing graft-versus-host disease. Together, these results support Allo15 MCAR-NKT cells as a next-generation, off-the-shelf immunotherapy with strong therapeutic potential for TNBC, particularly in the context of metastasis, immune evasion, and treatment resistance. The online version contains supplementary material available at 10.1186/s13045-025-01736-9.
Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer
PLOS One 2025 May
Abstract
Trogocytosis is an underappreciated phenomenon that shapes the immune microenvironment surrounding many types of solid tumors. The consequences of membrane-bound proteins being deposited from a donor immune cell to a recipient cancer cell via trogocytosis are still unclear. Here, we report that human clear cell renal carcinoma tumors stably express the lymphoid markers CD45, CD56, CD14, and CD16. Flow cytometry performed on fresh kidney tumors revealed consistent CD45 expression on tumor cells, as well as varying levels of the other markers mentioned previously. These results were consistent with our immunofluorescent analysis, which also revealed colocalization of lymphoid markers with carbonic anhydrase 9, a standard kidney tumor marker. RNA analysis showed a significant upregulation of genes typically associated with immune cells by tumor cells. Finally, we show evidence of chromosomal DNA being transferred from immune cells to tumor cells through physical contact. This horizontal gene transfer has transcriptional consequences in the recipient tumor cell, resulting in a fusion phenotype that expresses both immune and cancer specific proteins. This work demonstrates a novel mechanism by which tumor cell protein expression is altered through the acquisition of surface membrane fragments and genomic DNA from infiltrating lymphocytes. These results alter the way in which we understand tumor-immune cell interactions and may reveal new insights into the mechanisms by which tumors develop. Additionally, further studies into trogocytosis and other mechanisms of contact-mediated cellular transfer will help push the field towards the next generation of immunotherapies and biomarkers for treating renal cell carcinoma and other cancers.
更多信息
| 物种 | 人类 |
|---|---|
| Contains | • Anti-human CD3 monospecific antibody complex • Anti-human CD28 monospecific antibody complex • Anti-human CD2 monospecific antibody complex • Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20 |
相关产品
-
ImmunoCult™ 人CD3/CD28 T细胞激活剂cGMP，人T细胞激活扩增试剂
-
ImmunoCult™ XF培养基cGMP，无血清和无异种成分培养基，用于人T细胞扩增
THIS PRODUCT IS MANUFACTURED AND TESTED FOLLOWING RELEVANT CGMPs UNDER A CERTIFIED QUALITY MANAGEMENT SYSTEM. PRODUCT IS FOR INVESTIGATIONAL OR RESEARCH USE. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. 欲获悉更多关于STEMCELL的质控信息，请访问 WWW.STEMCELL.COM/COMPLIANCE.
沪公网安备31010102008431号
在线联系